USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Biotherm, Inc.
Address:
5301 Departure Drive
Raleigh, NC 27604
Phone:
N/A
URL:
N/A
EIN:
562098302
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $325,000.00 5
SBIR Phase II $2,249,999.00 4

Award List:

PORTABLE SYSTEM FOR CONTROL OF ANTICOAGULANT THERAPY

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Bruce J Oberhardt Phd
Abstract:
N/a

PORTABLE SYSTEM FOR CONTROL OF ANTICOAGULANT THERAPY

Award Year / Program / Phase:
1988 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Bruce J Oberhardt Phd
Abstract:
Biotherm, inc. proposes to design and develop a portable system, analogous to a hand-held glucose meter, to permit rapid, convenient blood coagulation testing on freshly drawnsamples from patients undergoing anticoagulant therapy. this cost-effective system would better help meet the needs of… More

RAPID FIBRINOGEN ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Bruce J Oberhardt
Abstract:
N/a

DRUG CHALLENGE ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Oberhardt, Bruce J , Principal Investigator
Abstract:
N/a

RAPID FIBRINOGEN ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Bruce J Oberhardt
Abstract:
An assay system for monitoring functional fibrinogen in patients undergoing thrombolytic therapy will be developed. this system will be based on a novel dry reagent assay technology that has recently been applied successfully to ptand activated ptt tests. introduction of a rapid, convenient,… More

DRUG CHALLENGE ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Oberhardt, Bruce J , Principal Investigator
Abstract:
A test system for rapid screening of patients prior to initiation of thrombolytic therapy will be developed. this system will be based on a novel dry reagent assay technology which recently has been applied successfully to pt and activated ptt tests. introduction of a rapid convenient test of… More

Rapid Monitoring of Antithrombin Agents

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Bruce Oberhardt
Abstract:
N/a

Rapid Immunoassay for Acute Myocardial Injury Detection

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Bruce Oberhardt
Abstract:
Phase I is directed at the development of a rapid and quantitative diagnostic immunoassay for acuteinjury. This immunoassay will utilize a proven dry chemistry test system incorporating a cardiac-spechemically conjugated to active-site inactivated coagulation factor Xa. The test principle… More

Rapid Monitoring of Antithrombin Agents

Award Year / Program / Phase:
1996 / SBIR / Phase II
Award Amount:
$749,999.00
Agency:
HHS
Principal Investigator:
Bruce Oberhardt
Abstract:
A functional assay system for monitoring antithrombin drugs, such as recombinant hirudin andhirudin analogs, in patients will be developed. This assay system will be based on a novel dry reagentparamagnetic particle-based assay technology that has recently been applied successfully to wholeblood,… More